Nonalcoholic fatty liver disease combined with dyslipidemia: the role of ursodeoxycholic acid in complex therapy


DOI: https://dx.doi.org/10.18565/pharmateca.2025.1.111-117

O.D. Ostroumova, S.V. Litvinova, A.I. Kochetkov, N.A. Plotnikova, M.V. Klepikova, S.S. Eremina, S.V. Cheremushkin

1) Russian Medical Academy of Continuous Professional Education of the Ministry of Healthcare of the Russian Federation, Moscow, Russia; 2) I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia; 3) Russian University of Medicine, Moscow, Russia
Nonalcoholic fatty liver disease (NAFLD) is one of the most common chronic liver diseases, affecting up to 30% of the adult population. It is closely associated with metabolic disorders such as obesity, type 2 diabetes mellitus and dyslipidemia, which increase the risk of cardiovascular diseases (CVD). Patients with NAFLD have a 2–3 times higher risk of developing CVD compared to the general population, which emphasizes the need for a comprehensive approach to treatment. One of the promising drugs for the treatment of NAFLD is ursodeoxycholic acid (UDCA), which, due to its cytoprotective, antioxidant, anti-inflammatory and immunomodulatory properties, not only reduces liver steatosis and fibrosis, but also reduces the risk of cardiovascular complications. The effectiveness of UDCA has been confirmed by numerous studies, including in combination therapy with statins. Studies demonstrate improvement in lipid profile and reduction in liver injury with UDCA treatment, making UDCA an important component of therapy for NAFLD and associated dyslipidemia.
Keywords: ursodeoxycholic acid, nonalcoholic fatty liver disease, dyslipidemia
Read entire article

About the Autors

Olga D. Ostroumova, Dr. Sci. (Med.), Professor, Head of the Department of Therapy and Polymorbid Pathology named after Academician M.S. Vovsi, Russian Medical Academy of Continuous Professional Education; Professor of the Department of Clinical Pharmacology and Propaedeutics of Internal Diseases, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia; ostroumova.olga@mail.ru, ORCID: https://orcid.org/0000-0002-0795-8225; eLibrary SPIN: 3910-6585 (corresponding author)
Svetlana V. Litvinova, Cand. Sci. (Med.), Assistant of the Department of Therapy and Polymorbid Pathology named after Academician M.S. Vovsi, Russian Medical Academy of Continuous Professional Education, Moscow, Russia; batyukina.svetlana@yandex.ru, ORCID: https://orcid.org/0000-0003-1316-7654
Aleksey I. Kochetkov, Cand. Sci. (Med.), Associate Professor of the Department of Therapy and Polymorbid Pathology named after Academician M.S. Vovsi, Russian Medical Academy of Continuous Professional Education, Moscow, Russia; ak_info@list.ru, ORCID: https://orcid.org/0000-0001-5801-3742; eLibrary SPIN: 9212-6010
Natalia А. Plotnikova, Cand. Sci. (Med.), Associate Professor of the Department of Therapy and Polymorbid Pathology named after Academician
M.S. Vovsi, Russian Medical Academy of Continuous Professional Education, Moscow, Russia; na_tasah_90@mail.ru, ORCID: https://orcid.org/0000-0001-5454-9339
Maria V. Klepikova, Cand. Sci. (Med.), Associate Professor at the Department of Therapy and Polymorbid Pathology named after Academician M.S. Vovsi, Russian Medical Academy of Continuous Professional Education, Moscow, Russia; pelageam@yandex.ru, ORCID: https://orcid.org/0000-0003-4258-1889
Sofya S. Eremina, 2nd year resident of the Department of Therapy and Polymorbid Pathology named after Academician M.S. Vovsi, Russian Medical Academy of Continuous Professional Education, Moscow, Russia; sofya.eremina@mail.ru, ORCID: https://orcid.org/0000-0001-7989-354X
Sergey V. Cheremushkin, Cand. Sci. (Med.), Associate Professor of the Department of Propaedeutics of Internal Diseases and Gastroenterology, Russian University of Medicine, Moscow, Russia; svch555362@yandex.ru, ORCID: https://orcid.org/0000-0002-0982-2006


Similar Articles

Back to Content

Бионика Медиа